Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC

ArticleinJapanese Journal of Clinical Oncology 42(6):528-33 · March 2012with13 Reads
Impact Factor: 2.02 · DOI: 10.1093/jjco/hys042 · Source: PubMed

    Abstract

    Objective Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth
    factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with non-small cell lung cancer. Although
    the safety profile of these drugs is favorable, a small proportion of patients with EGFR mutation-positive non-small cell lung cancer must discontinue treatment because of adverse events such as interstitial lung
    disease and hepatotoxicity. Subsequent chemotherapy has not been optimized in such patients.